Last reviewed · How we verify
Foster BDP/Formoterol
Foster BDP/Formoterol is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
Foster combines beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.
Foster combines beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Foster BDP/Formoterol |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) |
| Target | Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Beclomethasone dipropionate acts as a glucocorticoid receptor agonist that suppresses inflammatory responses in the airways, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improving airflow. Together, these agents provide both anti-inflammatory and bronchodilatory effects for maintenance therapy.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
- ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression (PHASE4)
- Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (PHASE3)
- CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (PHASE4)
- BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate) (PHASE3)
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD (PHASE3)
- Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI) (PHASE2)
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease (PHASE3)
- Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foster BDP/Formoterol CI brief — competitive landscape report
- Foster BDP/Formoterol updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about Foster BDP/Formoterol
What is Foster BDP/Formoterol?
How does Foster BDP/Formoterol work?
What is Foster BDP/Formoterol used for?
Who makes Foster BDP/Formoterol?
What drug class is Foster BDP/Formoterol in?
What development phase is Foster BDP/Formoterol in?
What are the side effects of Foster BDP/Formoterol?
What does Foster BDP/Formoterol target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drugs
- Target: All drugs targeting Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol)
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing